Juan Vilaro, MD
Associate Professor, Cardiovascular Medicine; Medical Director Of Heart Transplant
Department:
MD-CARDIOLOGY
Business Phone:
(352) 265-0751
Business Email:
juan.vilaro@medicine.ufl.edu
About Juan Vilaro
My name is Dr. Juan Vilaro, and I am an associate professor of medicine in the division of cardiovascular medicine at the University of Florida. I received my medical degree from the University of Puerto Rico School of Medicine, completing a visiting clerkship in cardiovascular diseases at Mayo Clinic during the same tenure. I completed my residency in internal medicine at the University of Florida, serving as chief resident for the program. I then completed my training at UF, completing cardiology and advance heart failure/transplant cardiology fellowships. I’m board-certified in internal medicine and cardiovascular medicine, and my primary clinical interests are the evaluation and management of patients with advanced heart failure syndromes, including optimal patient selection for advanced therapies such as heart transplantation and different forms of mechanical circulatory support. In addition, I am also interested in devising new strategies for reducing hospital admissions in patients with chronic heart failure.
Accomplishments
Exemplary Teacher Award
2019
·
College of Medicine
Teaching Profile
Courses Taught
2018
MDC6001 Intro Clin Practice
Board Certifications
-
Cardiovascular DiseaseAmerican Board of Internal Medicine
-
Internal MedicineAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Advanced Heart Failure and Transplant Cardiology
- Cardiology
Areas of Interest
- Echocardiogram
- Heart Failure
- Heart Transplant
- Heart disease
- Hypertrophic cardiomyopathy
- Mechanical Circulatory Assist Device
- Valvular Disease
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0001-5294-5397
Publications
2023
Artificial intelligence guidance of advanced heart failure therapies: A systematic scoping review.
Frontiers in cardiovascular medicine.
10
[DOI] 10.3389/fcvm.2023.1127716.
[PMID] 36910520.
2023
Left Ventricular Assist Device Use in Minorities: An Analysis of the National Inpatient Sample.
ASAIO journal (American Society for Artificial Internal Organs : 1992).
[DOI] 10.1097/MAT.0000000000002046.
[PMID] 37788482.
2023
Pharmacological Therapy Optimization for Heart Failure: A Practical Guide for the Internist.
The American journal of medicine.
136(8):745-752
[DOI] 10.1016/j.amjmed.2023.04.033.
[PMID] 37148990.
2023
Prognostic Value of Frailty for Heart Failure Patients Undergoing Left Ventricular Assist Device Implantation: A Systematic Review.
Cardiology in review.
[DOI] 10.1097/CRD.0000000000000541.
[PMID] 36881614.
2023
Recurrent Cardiac Sarcoidosis and Giant Cell Myocarditis After Heart Transplant: A Case Report and Systematic Literature Review.
The American journal of cardiology.
207:271-279
[DOI] 10.1016/j.amjcard.2023.08.005.
[PMID] 37769570.
2023
Transthyretin Cardiac Amyloidosis Disguised as Light Chain Amyloidosis or Multiple Myeloma?
The American journal of cardiology.
210:85-92
[DOI] 10.1016/j.amjcard.2023.10.031.
[PMID] 37852567.
2023
Utilization of the percutaneous left ventricular support as bridge to heart transplantation across the United States: In-depth UNOS database analysis.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
42(11):1597-1607
[DOI] 10.1016/j.healun.2023.06.002.
[PMID] 37307906.
2022
Impact of Laparoscopic Sleeve Gastrectomy on Cardiovascular Pharmacotherapy in Left Ventricular Assist Device Patients.
Journal of cardiovascular pharmacology.
79(5):646-649
[DOI] 10.1097/FJC.0000000000001223.
[PMID] 35058410.
2021
Cardiac Amyloid for the Internist.
Cureus.
13(1)
[DOI] 10.7759/cureus.12915.
[PMID] 33654598.
2021
Cardiac sarcoidosis in the donor heart without extracardiac manifestations.
BMJ case reports.
14(4)
[DOI] 10.1136/bcr-2021-241902.
[PMID] 33875513.
2021
Hemodynamic effects of ivabradine use in combination with intravenous inotropic therapy in advanced heart failure.
Heart failure reviews.
26(2):355-361
[DOI] 10.1007/s10741-020-10029-x.
[PMID] 32997214.
2021
SARS-CoV-2 Infections among Recent Organ Recipients, March-May 2020, United States.
Emerging infectious diseases.
27(2):552-555
[DOI] 10.3201/eid2702.204046.
[PMID] 33327990.
2021
Ventricular Assist Device Implantation and Bariatric Surgery: A Route to Transplantation in Morbidly Obese Patients with End-Stage Heart Failure.
ASAIO journal (American Society for Artificial Internal Organs : 1992).
67(2):163-168
[DOI] 10.1097/MAT.0000000000001212.
[PMID] 32701629.
2020
Early versus standard renal replacement therapy after left ventricular assist device implantation.
Journal of cardiac surgery.
35(10):2529-2538
[DOI] 10.1111/jocs.14873.
[PMID] 32741013.
2020
Leadless pacemaker use in a patient with a durable left ventricular assist device.
Pacing and clinical electrophysiology : PACE.
43(9):1048-1050
[DOI] 10.1111/pace.13937.
[PMID] 32394443.
2020
Patterns of emergency department utilization for LVAD patients compared with non-LVAD patients.
International journal of cardiology. Heart & vasculature.
30
[DOI] 10.1016/j.ijcha.2020.100617.
[PMID] 32904266.
2020
PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
American heart journal.
230:35-43
[DOI] 10.1016/j.ahj.2020.09.012.
[PMID] 32980364.
2020
Reply: Advantage of leadless pacemaker over the conventional pacemaker in patients with left ventricular assist device.
Pacing and clinical electrophysiology : PACE.
43(10)
[DOI] 10.1111/pace.14057.
[PMID] 32895989.
2020
Severe COVID-19 After Recent Heart Transplantation Complicated by Allograft Dysfunction
JACC: Case Reports.
2(9):1347-1350
[DOI] 10.1016/j.jaccas.2020.05.066.
[PMID] 32835277.
2020
The quest for noninvasive predictors of pulmonary vascular resistance in heart transplant candidates.
Polish archives of internal medicine.
130(10):826-827
[DOI] 10.20452/pamw.15656.
[PMID] 33119221.
2020
Transcatheter aortic valve replacement 24 years after cardiac transplantation.
Journal of cardiac surgery.
35(3):710-712
[DOI] 10.1111/jocs.14438.
[PMID] 31971286.
2020
Utilizing the index for mortality prediction after cardiac transplantation risk score to predict hospital resource consumption.
Journal of cardiac surgery.
35(4):854-859
[DOI] 10.1111/jocs.14486.
[PMID] 32115823.
2019
Aortoventricular Index Predicts Long-Term Mortality After Transcatheter Aortic Valve Replacement.
JACC. Cardiovascular interventions.
12(22):2327-2329
[DOI] 10.1016/j.jcin.2019.07.033.
[PMID] 31753307.
2019
Electronic consults for improving specialty care access for veterans.
The American journal of managed care.
25(5):250-253
[PMID] 31120719.
2018
Effects of socioeconomic status on clinical outcomes with ventricular assist devices.
Clinical cardiology.
41(11):1463-1467
[DOI] 10.1002/clc.23070.
[PMID] 30225924.
2015
[Pulmonary crackles, what does the clinician hear?].
Revue des maladies respiratoires.
32(7):728-36
[DOI] 10.1016/j.rmr.2014.11.062.
[PMID] 26456376.
2014
Chest physiotherapy for acute wheezing: an inappropriate protocol in a misdiagnosed group of patients.
Acta paediatrica (Oslo, Norway : 1992).
103(8):e325-6
[DOI] 10.1111/apa.12652.
[PMID] 24702515.
1995
Endocarditis-associated paravalvular abscesses. Do clinical parameters predict the presence of abscess?
Chest.
107(4):898-903
[PMID] 7705150.
Grants
Aug 2021
ACTIVE
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failure with Reduced Ejection Fraction Who Have Been Stabilized During Hospitalization for Acute Heart Failure
Role: Principal Investigator
Funding: BRIGHAM AND WOMENS HOSPITAL
via ASTRAZENECA
Jan 2021
– Aug 2023
The optimal loop diuretic: mechanistic insights from longitudinal changes in blood and urine proteins to explain efficacy and safety of torsemide vs furosemide after a heart failure hospitalization
Role: Principal Investigator
Funding: INOVA HEALTH CARE SERVICES
via NATL INST OF HLTH NHLBI
Sep 2019
– Dec 2022
A multicenter, randomized, double-blind, double-dummy, parallel group, active controlled 8-week study to evaluate the effect of sacubitril/valsartan (LCZ696) versus valsartan on changes in NT-proBNP and safety and tolerability of inhospital initiation of LCZ696 compared to valsartan in HFpEF patients with acute decompensated heart failure (ADHF) who have been stabilized during hospitalization
Role: Principal Investigator
Funding: NOVARTIS PHARMACEUTICALS CORP
Aug 2018
– Aug 2023
VICTORIA Heart Failure (HF) Registry
Characterizing the flow of patients hospitalized for heart failure decompensation during the prescreening phase of the VICTORIA (VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) Study
Role: Principal Investigator
Funding: DUKE UNIVERSITY
via MERCK SHARP & DOHME
Aug 2018
– Jul 2022
TRANSFORM-HF (ToRsemide compArisoN with furoSemide FOR Management of Heart Failure) Study
Role: Principal Investigator
Funding: YALE UNIV
via NATL INST OF HLTH NHLBI
Nov 2017
– Oct 2023
PROVIDE-HF: Patient Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (Sacubitril/Valsartan) in Heart Failure
Role: Principal Investigator
Funding: DUKE UNIVERSITY
via NOVARTIS PHARMACEUTICALS CORP
Nov 2017
ACTIVE
214 Fund – Vilaro Payroll Operating Account
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Apr 2017
– Feb 2019
A multicenter, randomized, double-blind, double dummy, parallel group, active-controlled 8-week study to evaluate the effect of sacubitril/valsartan (LCZ696) versus enalapril on changes in NT-proBNP and safety and tolerability of inhospital initiation of LCZ696 compared to enalapril in HFrEF patients who have been stabilized following
hospitalization for acute decompensated heart failure (ADHF)
Role: Principal Investigator
Funding: NOVARTIS PHARMACEUTICALS CORP
Dec 2016
– Sep 2023
A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) – VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)
Role: Principal Investigator
Funding: MERCK SHARP & DOHME
Feb 2016
– Sep 2019
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)
Role: Co-Investigator
Funding: BRIGHAM AND WOMENS HOSPITAL
via NATL INST OF HLTH NHLBI
Education
Fellowship – Cardiology – Heart Failure and Transplantation
2014-2015
·
University of Florida
Fellowship – Cardiology
2011-2014
·
University of Florida
Residency – Internal Medicine
2008-2010
·
University of Florida
Internship – Internal Medicine
2007-2008
·
University of Florida
Medical Degree
2007
·
University Puerto Rico
Contact Details
Phones:
- Business:
- (352) 265-0751
Emails:
- Business:
- juan.vilaro@medicine.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100288
1329 SW 16TH ST
GAINESVILLE FL 32608